Trial Information
IMRT With Concurrent Chemotherapy and Cetuximab Against Locoregionally Advanced NPC: a Phase 1 Study
Inclusion Criteria:
- Pathologically confirmed untreated NPC patients
- locoregionally advanced (T3-4 or N2-3 M0)
- 18-65 years
- with MRI examinations
- ECOG ≤ 2
- With written consent
Exclusion Criteria:
- Without a second cancer
- Pregnancy
- With other severe diseases (blood,liver ,kidney or heart diseases)
- Could not be staged properly
- Without written consent
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Number of Participants with Adverse Events as a Measure of Safety
Outcome Time Frame:
6 months
Safety Issue:
Yes
Principal Investigator
Xia He, M.D. Ph.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
Jiangsu Cancer Institute & Hospital
Authority:
China: Ethics Committee
Study ID:
LA-chemoR-c225
NCT ID:
NCT01712919
Start Date:
May 2010
Completion Date:
May 2013
Related Keywords:
- Nasopharyngeal Carcinoma
- Locoregionally advanced nasopharyngeal carcinoma
- cetuximab
- chemoradiation
- Carcinoma
- Nasopharyngeal Neoplasms